Cronos’ partnership with bioengineering company GinkgoBioworks anticipates commecialization of synthetic cultured rare cannabinoids by Q3. Off the radar for many. Been waiting 3 years for this to happen, now just a few months away. Health Canada ought to issue the commercial processing license shortly if all is on track to meet production/commercialization targets, and things are on track per recent conf. call. More attention to this business segment in the 4/26 Cantechletter featuring client report by Raymond James.
Transcript (2/26/21):
https://www.fool.com/earnings/call-transcripts/2021/02/26/cronos-group-inc-cron-q4-2020-earnings-call-transc/
Cantechletter (4/26/21):
https://www.cantechletter.com/2021/04/cronos-group-is-undervalued-says-raymond-james/